Opko Health (OPK) versus Corium International (CORI) Critical Review

Opko Health (NASDAQ: OPK) and Corium International (NASDAQ:CORI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility & Risk

Opko Health has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Corium International has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Opko Health and Corium International, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opko Health 0 2 5 0 2.71
Corium International 0 0 6 0 3.00

Opko Health presently has a consensus price target of $14.21, suggesting a potential upside of 187.16%. Corium International has a consensus price target of $13.00, suggesting a potential upside of 16.38%. Given Opko Health’s higher probable upside, analysts plainly believe Opko Health is more favorable than Corium International.

Valuation and Earnings

This table compares Opko Health and Corium International’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Opko Health $1.22 billion 2.27 -$25.08 million ($0.19) -26.05
Corium International $31.86 million 12.66 -$47.79 million ($1.67) -6.69

Opko Health has higher revenue and earnings than Corium International. Opko Health is trading at a lower price-to-earnings ratio than Corium International, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

22.9% of Opko Health shares are owned by institutional investors. Comparatively, 89.1% of Corium International shares are owned by institutional investors. 40.2% of Opko Health shares are owned by company insiders. Comparatively, 45.7% of Corium International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Opko Health and Corium International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opko Health -9.45% -5.17% -3.94%
Corium International -149.99% -482.64% -62.37%

Summary

Opko Health beats Corium International on 8 of the 14 factors compared between the two stocks.

Opko Health Company Profile

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply